buy

Regeneron Pharmaceuticals Inc. buy Guggenheim

Regeneron Pharmaceuticals Inc.

Start price

€530.00

/ 50%

Target price

01.05.26

Performance (%)

Price

Summary

This prediction is currently active. The BUY prediction by Guggenheim currently has a performance of . A total of was paid as dividends for this prediction. This prediction currently runs until 01.05.26. The prediction end date can be changed by Guggenheim at any time. Guggenheim has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Feedback

Performance without dividends (%)

Name	1w	1m
Regeneron Pharmaceuticals Inc.
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by Guggenheim for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren

Prediction Buy

Perf. (%)

Target price 716.364

Change

Ends at

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Guggenheim from $940.00 to $810.00. They now have a "buy" rating on the stock.

Ratings data for REGN provided by MarketBeat

Guggenheim